Here’s what you should know:
1. Takeda will take Stanford’s discoveries and accelerate them into treatments.
2. Through the partnership, Stanford will be able to license out the products for further development. Some Takeda researchers will participate in ongoing research projects.
3. Stanford will retain all intellectual property.
4. Chaitan Khosla, director of Stanford ChEM-H (Chemistry, Engineering, and Medicine for Human Health), will oversee the program. She said in a release, “Stanford [Alliance for Innovative Medicines’] purpose is to accelerate the translation of Stanford’s cutting-edge discoveries into real treatments for human disease.”
More articles on quality:
How onboarding reduces patient anxiety — 4 key notes
25 states with the highest ASC hospital transfers and admissions
Are physicians ‘annoyed’ by empowered patients? 5 thoughts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.